Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock Short Interest Declines 85.9%

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) saw a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 2,442 shares, a drop of 85.9% from the October 15th total of 17,259 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 35,837 shares, the short-interest ratio is currently 0.1 days.

Insider Transactions at Frazier Life Sciences Acquisition Corp. II

In other news, CEO Albert Cha purchased 300,000 shares of the stock in a transaction on Thursday, October 15th. The stock was bought at an average price of $10.00 per share, with a total value of $3,000,000.00. Following the transaction, the chief executive officer owned 300,000 shares in the company, valued at $3,000,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research note on Saturday, October 24th.

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC traded down $0.05 during trading on Thursday, reaching $10.14. 41,427 shares of the company’s stock were exchanged, compared to its average volume of 31,676. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.08 and a 1 year high of $10.63.

About Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.